Search clinical trials for: Bepotastine besilate

Total 1387 results

Novartis

Completed

Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen

Seasonal Allergic Rhinitis

United Kingdom
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor

United States
Chung-Ang University Gwangmyeong Hospital

Not yet recruiting

Comparison of Remimazolam and Propofol Combination vs. Propofol in IOM

Neurologic Disorder
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk (TOGETHER)

Hypertension | Dyslipidemia

United States
Novartis
National Cancer Institute (NCI)

Completed

STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Leukemia

United States
Renmin Hospital of Wuhan University

Recruiting

Endoscopic Hemostatic and Sedative Treatment of Esophageal and Gastric Variceal Bleeding

Sedation | Endoscopic Hemostasis

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma

Sarcoma,Soft Tissue | Trunk | Extremity | Intensity-modulated Radiotherapy | Major Wound Complications | Targetd Therapy

China
The First Affiliated Hospital of Soochow University

Recruiting

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

CML, Chronic Phase; TKI

China
Asan Medical Center

Active, not recruiting

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Gastrointestinal Stromal Tumors

Korea, Republic of
Yuhong Li

Completed

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment (Poetry-1)

Esophageal Squamous Cell Carcinoma

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib (CML0609)

Chronic Myeloid Leukaemia

Italy
First Affiliated Hospital of Harbin Medical University

Terminated

Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

Ovarian Cancer

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck

Adenoid Cystic Carcinoma

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study (RASS)

Sarcoma | Head and Neck Cancer | Soft Tissue and Bone Tumor

China
Centre Oscar Lambret
Novartis; National Cancer Institute, France

Terminated

Imatinib in Adult Patients With Metastatic Ocular Melanoma (O-Mel-Inib)

Melanoma

France
Novartis Pharmaceuticals

No longer available

Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination (MACS2226)

Gastrointestinal Stromal Tumor

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Italy
Azienda Ospedaliera Universitaria Policlinico
Università Politecnica delle Marche

Unknown

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Systemic Sclerosis

Italy
Central European Leukemia Study Group

Unknown

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Chronic Myeloid Leukemia

Austria
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Leukemia

United States
Harbin Medical University

Not yet recruiting

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Biliary Tract Cancer
Tongji Hospital

Recruiting

Continuous Infusion of Remidazolam for Colonoscopic Polypectomy in Elderly Patients

Colon Disease

China
Zhejiang University

Recruiting

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma (CAPT)

Hepatocellular Carcinoma

China
Asan Medical Center

Completed

A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs

Gastrointestinal Stromal Tumors (GISTs)

Korea, Republic of
Hubei Cancer Hospital

Enrolling by invitation

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

NSCLC

China
Peking University Cancer Hospital & Institute
Peking University First Hospital; Shanxi Province Cancer Hospital; Peking University... and other collaborators

Completed

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

Breast Cancer
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Second-line Treatment

China
Qianfoshan Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer

Immune Checkpoint Inhibition

China
University Hospital, Bordeaux

Completed

Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib (STIM 2)

Chronic Myeloid Leukaemia

France
Tianjin Medical University Cancer Institute and...
Zhejiang Cancer Hospital; Fudan University; Liaoning Tumor Hospital & Institute; Gansu Cancer Hospital

Unknown

Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

Soft Tissue Sarcoma, Adult, Stage II

China
Kerman University of Medical Sciences

Terminated

Population Pharmacokinetics of Imatinib in CML Patients in Iran

Chronic Myelogenous Leukemia

Iran, Islamic Republic of
Hospital Virgen de la Salud

Completed

Imatinib in KIT-negative Systemic Mastocytosis

Systemic Mastocytosis

Spain
Novartis

Completed

Effect of Food on Bioavailability of Modified Release Formulations of Imatinib

Healthy
Assistance Publique Hopitaux De Marseille

Unknown

Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index (GIGIST)

Gastrointestinal Stromal Tumor
Novartis Pharmaceuticals

Terminated

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) (IMPRES Extn)

Pulmonary Arterial Hypertension

Spain, Germany, Belgium, Switzerland, United States, Netherlands, Austria, Canada, Korea, Republic of, Italy, Japan, United Kingdom, France
Novartis Pharmaceuticals

Terminated

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Germany, Belgium, United Kingdom, United States, Lithuania, Italy, Australia
Novartis Pharmaceuticals

Completed

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Gastrointestinal Stromal Tumors

United States, France, Italy
Renato Melaragno

Unknown

Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+)

Brazil
Hadassah Medical Organization
Novartis

Withdrawn

Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.

Metastatic Solid Tumors.

Israel
University of Bologna
Novartis

Unknown

Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias

Myeloproliferative Disorders | Hypereosinophilic Syndrome | Chronic Eosinophilic Leukemia (CEL)

Italy
Fudan University

Unknown

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Tumor

China
Fudan University

Recruiting

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

Gastric Cancer | Metastasis

China
Peking University People's Hospital

Completed

Apatinib for Inoperable Advanced Chondrosarcoma (AIAC)

Efficacy | Toxicity, Drug

China
Guangzhou Institute of Respiratory Disease
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma (Spark-AL003)

Lung Carcinoma

China
Sun Yat-sen University

Unknown

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Non-small Cell Lung Cancer

China
University of Oxford
Johns Hopkins Bloomberg School of Public Health; University of Otago; Patan Academy...

Completed

PCV10 Immunogenicity Study Nepal 2015

Streptococcus Pneumoniae

United Kingdom
Cancer Institute and Hospital, Chinese Academy...

Unknown

Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

Differentiated Thyroid Carcinoma

China
Heidelberg University
Novartis

Completed

Study to Evaluate Imatinib in Desmoid Tumors

Desmoid Tumor | Aggressive Fibromatosis

Germany
Tianjin Medical University Cancer Institute and...

Unknown

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) (HCC)

Hepatocellular Carcinoma

China

Search clinical trials for: Bepotastine besilate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations